PharmaMedic /
  • Home
  • Our Services
    • Start-Up
    • Product Launch
    • Product Development
  • Join Us
  • About Us
    • Our Vision
    • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us
PharmaMedic
  • Home
  • Our Services
    • Start-Up
    • Product Launch
    • Product Development
  • Join Us
  • About Us
    • Our Vision
    • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us

#VPAS

Tag

Will ABPI’s ambitious VPAG plans succeed VPAS?

Will ABPI’s ambitious VPAG plans succeed VPAS?

Discussions are beginning on the next iteration of the UK’s voluntary scheme for branded medicines, pricing and access (VPAS) and the Association of the British Pharmaceutical Industry (ABPI) has set out its stall to government. It has published a four-point proposal for a Voluntary Scheme for Pricing, Access and Growth (VPAG), designed to reignite competitiveness and boost innovation in the life sciences sector, thereby improving health outcomes and the wider economy.

15 May 2023
Read More
The 2023 ABPI annual conference focused on growing the Life Sciences

The 2023 ABPI annual conference focused on growing the Life Sciences

The 2023 annual conference of the UK’s Association of the British Pharmaceutical Industry (ABPI) at the end of April had a theme of Growing the UK as a Global Hub for Life Sciences.

9 May 2023
Read More
Government confirms increase to pharma’s statutory scheme

Government confirms increase to pharma’s statutory scheme

Despite opposition from the Association of the British Pharmaceutical Industry (ABPI), the UK government has confirmed its plans to raise the revenue clawback rate paid by pharma for branded medicines under the statutory scheme by just over 3%, from 24.4% to 27.5% for 2023.

9 Mar 2023
Read More
ABPI asks UK government to review VPAS as clawback will hit 26.5% of sales revenue in 2023

ABPI asks UK government to review VPAS as clawback will hit 26.5% of sales revenue in 2023

In 2023 manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government under the 2019 Voluntary scheme for branded medicines, pricing and access (VPAS), according to the Association of the British Pharmaceutical Industry (ABPI).

20 Dec 2022
Read More

Categories

  • Awards
  • Consultants
  • Events
  • News
    • General
    • Medical Affairs
    • Rare diseases
  • Our Services
  • Regulatory
  • Resources
    • White Paper

Tags

#ABPI #BIA #cancer #ClinicalTrials #diagnostics #drugdevelopment #drugpricing #drugregulation #EC #EFPIA #EMA #EU #FDA #HTA #innovation #lifesciences #marketaccess #MDR #medicaldevice #medicaldeviceregulation #medicinesaccess #medtech #mentalhealth #mhra #NHS #NICE #pharmaregulation #pre-eclampsia #R&D #rarediseases #regulation #regulatory #research #UKgovernment #ukregulation #VPAS AI Biotech COVID-19 Healthcare IR35 Medical Affairs medicaldevices Pharma UKmedicines
PharmaMedic
  • Home
  • Join Us
  • Our Vision
  • Dr Malcolm Barratt-Johnson
  • Resources
  • News
  • Contact Us
Our Services
  • Start-Up
  • Product Launch
  • Product Development
Legal
  • Privacy Policy
  • Cookie Policy
Contact us
  • T:+44 (0) 208 168 1668
  • US Toll Free:+1 628 201 0911
  • [javascript protected email address]
  • The London Bioscience Innovation Centre (LBIC)
    2 Royal College Street
    London NW1 0NH

©2023 PharmaMedic. All Rights Reserved | Company Registration Number: 07364364 | VAT: 135986768

Powered by FL1 Digital